Please login to the form below

Not currently logged in
Email:
Password:

RNA interference

This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.

FDA clears Alnylam’s second RNAi drug for rare disease

FDA clears Alnylam’s second RNAi drug for rare disease

Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari.

Latest news

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics